Zhongzhi Pharmaceutical Holdings Limited EBIT

Zhongzhi Pharmaceutical Holdings Limited's ebit stands at $32M as of June 2026. That compares with $270M in the prior-year period — down 88.1% year over year. That is below the sector sector average of $2.6T. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Zhongzhi Pharmaceutical Holdings Limited reported $32M in EBIT versus $270M a year earlier — a 88.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Zhongzhi Pharmaceutical Holdings Limited sits lower the its sector benchmark ($2.6T) with a EBIT of $32M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $270M in the prior-year period — down 88.1% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Zhongzhi Pharmaceutical Holdings Limited's EBIT evolved across reporting periods, while the comparison chart places 3737.HK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.